Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MB-CART2219.1 |
| Synonyms | |
| Therapy Description |
MB-CART2219.1 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD22 and CD19, which potentially enhances antitumor immune response (Transplant Cell Ther 31, no. 2 (2025): S11). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MB-CART2219.1 | MB-CART-2219.1|MB-CART 2219.1 | CD19 Immune Cell Therapy 72 CD22 Immune Cell Therapy 13 | MB-CART2219.1 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD22 and CD19, which potentially enhances antitumor immune response (Transplant Cell Ther 31, no. 2 (2025): S11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07108868 | Phase I | MB-CART2219.1 | A Phase I Dose Finding Study of MB-CART2219.1 | Recruiting | DEU | 0 |